Genetic predeterminants and recent advancements in steatotic liver disease: A roadmap toward precision hepatology

Figure 1 Global prevalence of metabolic dysfunction-associated steatotic liver disease, based on the systematic review and meta-analysis by Younossi et al[14]. The map displays regional variation in metabolic dysfunction-associated steatotic liver disease prevalence, with the highest rates observed in Latin America (44.37%) and the Middle East and North Africa (MENA; 36.5%), followed by Southeast Asia (33.07%), North America (31.2%), and Australia (31.2%). Western Europe and East Asia show lower rates at 25.1% and 29.71%, respectively. These differences likely reflect a combination of genetic predisposition (e.g., PNPLA3 and TM6SF2 allele frequencies), dietary patterns, urbanization, and metabolic comorbidities[14].